NeuBase to Participate at the Jefferies Healthcare Conference
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced its participation in the Jefferies Healthcare Conference in New York from June 8-10, 2022. CEO Dietrich A. Stephan will present a corporate overview on June 10, from 9:00 am to 9:25 am ET. NeuBase focuses on innovative precision genetic medicines, utilizing its proprietary PATrOL™ platform to target disease-causing mutations, particularly in neuromuscular and oncologic disorders. A webcast replay will be available for 90 days following the presentation.
- None.
- None.
PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that company management will present a corporate overview at the Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.
| Jefferies Healthcare Conference | |
| Date: | Friday, June 10 |
| Time: | 9:00am – 9:25am ET |
| Speaker: | Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer and Chairman |
A replay of the webcast will be available following the presentation for 90 days. To access the webcast, please click here. Please contact your representative at Jefferies to schedule a one-on-one meeting with NeuBase management during the conference.
About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that Drug the Genome™. The Company’s therapies are built on a proprietary platform called PATrOL™ that encompasses a novel peptide-nucleic acid antisense oligonucleobase technology combined with a novel delivery shuttle that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions, who currently have limited to no treatment options. To learn more, visit www.neubasetherapeutics.com.
NeuBase Investor Contact:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
OP: (617) 430-7576
NeuBase Media Contact:
Jessica Yingling, Ph.D.
President
Little Dog Communications Inc.
jessica@litldog.com
OP: (858) 344-8091
FAQ
What is NeuBase Therapeutics presenting at the Jefferies Healthcare Conference?
When is the Jefferies Healthcare Conference?
Who is the speaker for NeuBase at the conference?
How can I access the NeuBase presentation after the conference?
What is the focus of NeuBase Therapeutics' research?
